Earl Martin Douglas

Insider · SVP, General Counsel · ALLO

Earl Martin Douglas files insider transactions with the SEC as a svp, general counsel of Allogene Therapeutics (ALLO). We hold 2 disclosed purchases and sales filed since 17 January 2007, 1 of them in the last 90 days.

Files forALLO
Disclosed buys and sells2 in all, 1 in the last 90 days
Last disclosure25 August 2026

Positions held

2 posts we hold — a term names its own dates; a run of filings only says when they filed

Filed 14 August 2023 — 21 August 2026SVP, General Counsel · Allogene Therapeutics (ALLO)16 Form 4 lines · source: SEC Form 4
Filed 16 January 2007 — 28 March 2012General Counsel · Biomimetic Therapeutics (BMTI)57 Form 4 lines · source: SEC Form 4

Everything they disclosed

73 entries, newest first — one per disclosure report, one per Form 4 line

▼ sold on the open market 29,697 shares of Allogene TherapeuticsSEC Form 425 August 2026Common Stock · traded 21 August 2026 · filed 25 August 2026
▼ sold on the open market 22,900 shares of Allogene TherapeuticsSEC Form 44 February 2026Common Stock · traded 2 February 2026 · filed 4 February 2026
was granted 539,072 shares of Allogene Therapeutics (a derivative holding)SEC Form 44 February 2026Stock Option (Right to buy) · traded 2 February 2026 · filed 4 February 2026
was granted 152,480 shares of Allogene Therapeutics (a derivative holding)SEC Form 44 February 2026Restricted Stock Unit · traded 2 February 2026 · filed 4 February 2026
was granted 539,072 shares of Allogene Therapeutics (a derivative holding)SEC Form 44 February 2026Stock Option (Right to buy) · traded 2 February 2026 · filed 4 February 2026
was granted 152,480 shares of Allogene Therapeutics (a derivative holding)SEC Form 44 February 2026Restricted Stock Unit · traded 2 February 2026 · filed 4 February 2026
▼ sold on the open market 22,900 shares of Allogene TherapeuticsSEC Form 44 February 2026Common Stock · traded 2 February 2026 · filed 4 February 2026
▼ sold on the open market 6,404 shares of Allogene TherapeuticsSEC Form 45 February 2025Common Stock · traded 3 February 2025 · filed 5 February 2025
was granted 512,370 shares of Allogene Therapeutics (a derivative holding)SEC Form 428 January 2025Stock Option (Right to buy) · traded 24 January 2025 · filed 28 January 2025
was granted 144,928 shares of Allogene TherapeuticsSEC Form 428 January 2025Common Stock · traded 24 January 2025 · filed 28 January 2025
had shares withheld for tax on 28,310 shares of Allogene TherapeuticsSEC Form 423 August 2024Common Stock · traded 21 August 2024 · filed 23 August 2024
was granted 147,778 shares of Allogene Therapeutics (a derivative holding)SEC Form 431 January 2024Stock Option (Right to buy) · traded 25 January 2024 · filed 31 January 2024
was granted 41,800 shares of Allogene TherapeuticsSEC Form 431 January 2024Common Stock · traded 25 January 2024 · filed 31 January 2024
was granted 960,854 shares of Allogene Therapeutics (a derivative holding)SEC Form 417 August 2023Stock Option (Right to Buy) · traded 14 August 2023 · filed 17 August 2023
was granted 108,958 shares of Allogene TherapeuticsSEC Form 417 August 2023Common Stock · traded 14 August 2023 · filed 17 August 2023
was granted 326,876 shares of Allogene TherapeuticsSEC Form 417 August 2023Common Stock · traded 14 August 2023 · filed 17 August 2023
▼ sold on the open market 1,100 shares of Biomimetic TherapeuticsSEC Form 428 March 2012Common Stock · traded 26 March 2012 · filed 28 March 2012
▼ sold on the open market 5,000 shares of Biomimetic TherapeuticsSEC Form 428 March 2012Common Stock · traded 27 March 2012 · filed 28 March 2012
▼ sold on the open market 5,000 shares of Biomimetic TherapeuticsSEC Form 428 March 2012Common Stock · traded 28 March 2012 · filed 28 March 2012
▼ sold on the open market 1,100 shares of Biomimetic TherapeuticsSEC Form 428 March 2012Common Stock · traded 28 March 2012 · filed 28 March 2012
▼ sold on the open market 200 shares of Biomimetic TherapeuticsSEC Form 428 March 2012Common Stock · traded 28 March 2012 · filed 28 March 2012
▼ sold on the open market 3,300 shares of Biomimetic TherapeuticsSEC Form 428 March 2012Common Stock · traded 28 March 2012 · filed 28 March 2012
▼ sold on the open market 1,400 shares of Biomimetic TherapeuticsSEC Form 428 March 2012Common Stock · traded 28 March 2012 · filed 28 March 2012
▼ sold on the open market 6,000 shares of Biomimetic TherapeuticsSEC Form 428 March 2012Common Stock · traded 28 March 2012 · filed 28 March 2012
▼ sold on the open market 3,000 shares of Biomimetic TherapeuticsSEC Form 428 March 2012Common Stock · traded 28 March 2012 · filed 28 March 2012
▼ sold on the open market 5,000 shares of Biomimetic TherapeuticsSEC Form 428 March 2012Common Stock · traded 28 March 2012 · filed 28 March 2012
▼ sold on the open market 1,300 shares of Biomimetic TherapeuticsSEC Form 428 March 2012Common Stock · traded 28 March 2012 · filed 28 March 2012
▼ sold on the open market 400 shares of Biomimetic TherapeuticsSEC Form 428 March 2012Common Stock · traded 28 March 2012 · filed 28 March 2012
▼ sold on the open market 300 shares of Biomimetic TherapeuticsSEC Form 428 March 2012Common Stock · traded 28 March 2012 · filed 28 March 2012
▼ sold on the open market 2,000 shares of Biomimetic TherapeuticsSEC Form 428 March 2012Common Stock · traded 28 March 2012 · filed 28 March 2012
▼ sold on the open market 5,000 shares of Biomimetic TherapeuticsSEC Form 428 March 2012Common Stock · traded 28 March 2012 · filed 28 March 2012
▼ sold on the open market 5,000 shares of Biomimetic TherapeuticsSEC Form 428 March 2012Common Stock · traded 28 March 2012 · filed 28 March 2012
▼ sold on the open market 461 shares of Biomimetic TherapeuticsSEC Form 428 March 2012Common Stock · traded 28 March 2012 · filed 28 March 2012
▼ sold on the open market 8,000 shares of Biomimetic TherapeuticsSEC Form 428 March 2012Common Stock · traded 28 March 2012 · filed 28 March 2012
was granted 80,000 shares of Biomimetic Therapeutics (a derivative holding)SEC Form 42 March 2012Stock Options (right to buy) · traded 29 February 2012 · filed 2 March 2012
▼ sold on the open market 3,000 shares of Biomimetic TherapeuticsSEC Form 414 October 2011Common Stock · traded 12 October 2011 · filed 14 October 2011
▼ sold on the open market 3,000 shares of Biomimetic TherapeuticsSEC Form 414 October 2011Common Stock · traded 13 October 2011 · filed 14 October 2011
▼ sold on the open market 3,000 shares of Biomimetic TherapeuticsSEC Form 414 October 2011Common Stock · traded 14 October 2011 · filed 14 October 2011
▼ sold on the open market 3,000 shares of Biomimetic TherapeuticsSEC Form 411 October 2011Common Stock · traded 6 October 2011 · filed 11 October 2011
▼ sold on the open market 3,000 shares of Biomimetic TherapeuticsSEC Form 411 October 2011Common Stock · traded 7 October 2011 · filed 11 October 2011
▼ sold on the open market 3,000 shares of Biomimetic TherapeuticsSEC Form 411 October 2011Common Stock · traded 10 October 2011 · filed 11 October 2011
▼ sold on the open market 3,000 shares of Biomimetic TherapeuticsSEC Form 411 October 2011Common Stock · traded 11 October 2011 · filed 11 October 2011
▼ sold on the open market 3,000 shares of Biomimetic TherapeuticsSEC Form 45 October 2011Common Stock · traded 3 October 2011 · filed 5 October 2011
▼ sold on the open market 3,000 shares of Biomimetic TherapeuticsSEC Form 45 October 2011Common Stock · traded 4 October 2011 · filed 5 October 2011
▼ sold on the open market 3,000 shares of Biomimetic TherapeuticsSEC Form 45 October 2011Common Stock · traded 5 October 2011 · filed 5 October 2011
was granted 40,000 shares of Biomimetic Therapeutics (a derivative holding)SEC Form 421 January 2011Stock Options (right to buy) · traded 19 January 2011 · filed 21 January 2011
exercised options over 18,000 shares of Biomimetic Therapeutics (a derivative holding)SEC Form 419 March 2010Stock Options (right to buy) · traded 17 March 2010 · filed 19 March 2010
exercised options over 7,500 shares of Biomimetic Therapeutics (a derivative holding)SEC Form 419 March 2010Stock Options (right to buy) · traded 17 March 2010 · filed 19 March 2010
exercised options over 18,000 shares of Biomimetic TherapeuticsSEC Form 419 March 2010Common Stock · traded 17 March 2010 · filed 19 March 2010
exercised options over 7,500 shares of Biomimetic TherapeuticsSEC Form 419 March 2010Common Stock · traded 17 March 2010 · filed 19 March 2010
had shares withheld for tax on 6,975 shares of Biomimetic TherapeuticsSEC Form 419 March 2010Common Stock · traded 17 March 2010 · filed 19 March 2010
▼ sold on the open market 4,430 shares of Biomimetic TherapeuticsSEC Form 419 March 2010Common Stock · traded 17 March 2010 · filed 19 March 2010
▼ sold on the open market 570 shares of Biomimetic TherapeuticsSEC Form 419 March 2010Common Stock · traded 17 March 2010 · filed 19 March 2010
was granted 40,000 shares of Biomimetic Therapeutics (a derivative holding)SEC Form 45 February 2010Stock Options (right to buy) · traded 3 February 2010 · filed 5 February 2010
exercised options over 34,000 shares of Biomimetic Therapeutics (a derivative holding)SEC Form 414 January 2010Stock Options (right to buy) · traded 2 January 2010 · filed 14 January 2010
exercised options over 37,000 shares of Biomimetic Therapeutics (a derivative holding)SEC Form 414 January 2010Stock Options (right to buy) · traded 13 January 2010 · filed 14 January 2010
exercised options over 34,000 shares of Biomimetic TherapeuticsSEC Form 414 January 2010Common Stock · traded 2 January 2010 · filed 14 January 2010
had shares withheld for tax on 10,345 shares of Biomimetic TherapeuticsSEC Form 414 January 2010Common Stock · traded 2 January 2010 · filed 14 January 2010
▼ sold on the open market 12,500 shares of Biomimetic TherapeuticsSEC Form 414 January 2010Common Stock · traded 13 January 2010 · filed 14 January 2010
▼ sold on the open market 299 shares of Biomimetic TherapeuticsSEC Form 414 January 2010Common Stock · traded 13 January 2010 · filed 14 January 2010
exercised options over 37,000 shares of Biomimetic TherapeuticsSEC Form 414 January 2010Common Stock · traded 13 January 2010 · filed 14 January 2010
▼ sold on the open market 1,200 shares of Biomimetic TherapeuticsSEC Form 418 March 2009Common Stock · traded 17 March 2009 · filed 18 March 2009
was granted 35,000 shares of Biomimetic Therapeutics (a derivative holding)SEC Form 42 March 2009Stock Options (right to buy) · traded 26 February 2009 · filed 2 March 2009
exercised options over 8,500 shares of Biomimetic Therapeutics (a derivative holding)SEC Form 416 April 2008Stock Options (right to buy) · traded 14 April 2008 · filed 16 April 2008
exercised options over 8,500 shares of Biomimetic TherapeuticsSEC Form 416 April 2008Common Stock · traded 14 April 2008 · filed 16 April 2008
▲ bought on the open market 1,000 shares of Biomimetic TherapeuticsSEC Form 41 April 2008Common Stock · traded 28 March 2008 · filed 1 April 2008
was granted 25,000 shares of Biomimetic Therapeutics (a derivative holding)SEC Form 425 February 2008Stock Options (right to buy) · traded 7 February 2008 · filed 25 February 2008
▲ bought on the open market 2,900 shares of Biomimetic TherapeuticsSEC Form 424 January 2008Common Stock · traded 23 January 2008 · filed 24 January 2008
▲ bought on the open market 100 shares of Biomimetic TherapeuticsSEC Form 424 January 2008Common Stock · traded 23 January 2008 · filed 24 January 2008
▲ bought on the open market 200 shares of Biomimetic TherapeuticsSEC Form 424 January 2008Common Stock · traded 23 January 2008 · filed 24 January 2008
▲ bought on the open market 300 shares of Biomimetic TherapeuticsSEC Form 424 January 2008Common Stock · traded 23 January 2008 · filed 24 January 2008
was granted 10,000 shares of Biomimetic Therapeutics (a derivative holding)SEC Form 411 September 2007Stock Options (right to buy) · traded 6 September 2007 · filed 11 September 2007
was granted 30,000 shares of Biomimetic Therapeutics (a derivative holding)SEC Form 417 January 2007Stock Options · traded 16 January 2007 · filed 17 January 2007

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.